Cerveau Technologies and the University of Wisconsin-Madison Alzheimer’s Disease Research Center in the US have signed an agreement to support various research projects studying the stages of Alzheimer’s Disease.
The clinical research agreement will also see the parties support research projects studying the stages of other neurodegenerative diseases.
The projects will use an early stage imaging agent (MK-6240) that will be used in Positron Emission Tomography (PET) scans to evaluate the status and progression of neurofibrillary tangles (NFTs) in the brain.
Wisconsin Alzheimer’s Disease Research Center associate director Dr Sterling Johnson said: “This collaborative tau imaging research programme will provide valuable information about the rates of progression across the Alzheimer’s Disease stages from preclinical to overt dementia.”
Under the terms of the agreement, Cerveau will back various research projects at the Wisconsin Alzheimer’s Disease Research Center and supply the MK-6240 precursor needed for the initiatives.
Cerveau Technologies president Rick Hiatt said: “At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health.
“We are excited by the opportunity to work with the Wisconsin Alzheimer’s Disease Research Center and the pharmaceutical industry to provide access to this novel imaging agent to the broader scientific community."
The programmatic focus of Wisconsin ADRC is on preclinical Alzheimer’s Disease.
It conducts clinical and basic science research regarding early identification, causes and treatments of Alzheimer’s Disease and related disorders.
Image: Histopathogic image of senile plaques seen in the cerebral cortex in a patient with Alzheimer disease of presenile onset. Photo: courtesy of User:KGH.
